<?xml version="1.0" encoding="UTF-8"?>
<p>Several studies suggest the importance of considering the glycosylation aspect for influenza vaccine design. During 2016â€“2017 influenza season, human H3N2 vaccine used at that time was not as effective as expected because of the loss of the HA glycosylation site at antigenic site B in the egg-produced vaccine, which emphasizes the need of considering protein glycosylation during vaccine design [
 <xref rid="B27" ref-type="bibr">27</xref>
 <xref rid="B28" ref-type="bibr">28</xref>].
</p>
